Cargando…
Updates in endocrine therapy for metastatic breast cancer
Endocrine therapy (ET) remains the mainstay of treatment for steroid hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC). Tumor resistance to hormone therapy has led to the development of novel endocrine drug combinations, transforming the landsc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Compuscript
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832960/ https://www.ncbi.nlm.nih.gov/pubmed/34609096 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0255 |